High baseline tau and ISR activation may lower the effective trazodone threshol…

Mechanistic description

Patients with elevated p-tau and ISR activation may require less trazodone exposure to show pharmacodynamic effects because the drug acts on an already engaged pathogenic node. The best use of this idea is as a stratification hypothesis nested within dose-finding studies rather than as a standalone efficacy thesis.

Mechanism / pathway

MAPT; EIF2AK3; EIF2S1; ATF4
→
neurodegeneration

Evidence for (3)

Phosphorylated eIF2alpha is enriched in tau-positive degenerating neurons, linking ISR activation to tau pathology.

PMID:12499843
PERK pathway inhibition prevents tau-mediated neurodegeneration in preclinical systems, supporting pathway dependence in tauopathy.

PMID:26450683
Trazodone reduced tau-linked neurodegeneration in mouse models.

PMID:28430857

Evidence against (3)

High p-tau and high ISR activation may instead mark more advanced, less reversible disease rather than greater dose sensitivity.

PMID:26450683
No human evidence currently shows that biomarker-high patients respond at lower trazodone doses.

PMID:35921312
Apparent subgroup effects could reflect regression to the mean or larger biomarker dynamic range rather than true threshold lowering.

PMID:12499843

Evidence matrix

3 supporting 3 contradicting

53% posterior support

Supporting

Phosphorylated eIF2alpha is enriched in tau-positive degenerating neurons, linking ISR activation to tau pathology. PMID:12499843
PERK pathway inhibition prevents tau-mediated neurodegeneration in preclinical systems, supporting pathway dependence in tauopathy. PMID:26450683
Trazodone reduced tau-linked neurodegeneration in mouse models. PMID:28430857

Contradicting

High p-tau and high ISR activation may instead mark more advanced, less reversible disease rather than greater dose sensitivity. PMID:26450683
No human evidence currently shows that biomarker-high patients respond at lower trazodone doses. PMID:35921312
Apparent subgroup effects could reflect regression to the mean or larger biomarker dynamic range rather than true threshold lowering. PMID:12499843

Bayesian persona consensus

53% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). High baseline tau and ISR activation may lower the effective trazodone threshol…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-2b25f4433e

BibTeX

@misc{scidex_hypothesis_h2b25f44,
  title        = {High baseline tau and ISR activation may lower the effective trazodone threshol…},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-2b25f4433e},
  note         = {SciDEX artifact hypothesis:h-2b25f4433e}
}